As part of our ongoing aim to bring you reports of new developments, we have added a review which summarises the outcomes from the MANDARA non-inferiority trial that investigated the efficacy and safety of benralizumab, compared with mepolizumab, as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis in adult patients aged 18 years and over.
Independent commentary for the review has been provided by Professor Pravin Hissaria, Head of the Clinical Immunology and Allergy Unit at Royal Adelaide Hospital, Senior Immunopathologist at SA Pathology and Clinical Professor in the Adelaide University Department of Medicine.
Please login below to download this issue (PDF)